XTAL Tech and Eli Lilly Enter $345M AI-Powered Bispecific Antibody Collaboration

Gelonghui November 5th | XtalPi announced that its wholly-owned subsidiary Ailux has reached a multi-target strategic cooperation and platform licensing agreement with Eli Lilly, with a total agreement value of up to $345 million, including tens of millions of dollars in upfront and near-term milestone payments. According to the agreement, Lilly can nominate multiple target groups, and Ailux will be responsible for designing and optimizing bispecific antibody candidate drugs. Ailux is eligible to receive tens of millions of dollars in upfront and near-term milestone payments, as well as subsequent R&D, registration, and commercial milestone payments. In addition, Lilly has the right to obtain the usage rights of Ailux's AI-powered bispecific antibody design platform.